First-timers Amy Articolo (Novo Nordisk), Erin Quirk (Terns Pharmaceuticals), and Rachel Zayas (AGED Diagnostics) join the Surfers and guest KOL Ian Rowe to identify the highest impact presentations and messages of NASH-TAG 2022.
NASH-TAG 2022 Wrap-Up: Finding New Disease Insights and Reconsidering Clinical Trial Design
The Surfers and “fifth Beatle” Jörn Schattenberg review the highs, lows and powerful moments of Day Two at NASH-TAG 2022.
Key Opinion Leaders Convene to Discuss Their Impressions from the First Day of NASH-TAG 2022.
Andrew Scott joins the Surfers to discuss the growing energy and impact of patient advocacy.
The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021.
Jörn Schattenberg joins the Surfers to discuss the NASH cost-effectiveness research and related findings on quality of life.
This conversation is part of SurfingNASH’s 2021 NAFLD Year-In-Review. Professor Kenneth Cusi of the University of Florida joins Louise Campbell and Roger Green to discuss
Surfing NASH’s 2021 NAFLD year-in-review looks at the roles of older and newer drugs, multi-specialty integration against the coming NASH pandemic, and cost-effective, patient-focused healthcare.
Alina Allen joins the Surfers to discuss major advances in knowledge about MRE as the foundational test for patients.
